The leading life science company Thermo Fisher Scientific has expanded its pharma services footprint with two new state-of-the-art facilities in Rheinfelden and Weil am Rhein, Germany. The new facility will help to meet accelerating demand for robust clinical supply chain services throughout Europe.
- The new sites will bring much-needed clinical supply chain continuity and specialized cold chain and cryogenic expertise across Europe and globally.
- These facilities feature innovative and highly automated technologies to optimize efficiency and quality across the pharma services supply chain.
The major investments and deals by Thermo Fisher Scientific are featured below:
Sep 2020: Thermo Fisher Scientific Inc., announced the opening of its new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri. the USA. The company has invested approximately $50 million for this expansion
July 2020: Thermo Fisher Scientific Inc. announced to develop manufacturing processes designed to create more effective cell therapies in partnership with biotechnology company Lyell Immunopharma.
May 2020: The Thermo Fisher Scientific announce an exclusive license agreement with MSAID GmbH, a software company transforming proteomics with deep learning, to develop and commercialize deep learning tools for proteomics. The agreement will make MSAID’s Prosit-derived framework widely accessible to proteomics laboratories.
May 2020: Thermo Fisher Scientific announced that it is constructing a new commercial manufacturing site in Plainville, Mass, the USA. The $180 million facility will double the company’s commercial viral vector capacity to support increasing demand for the development and manufacture of gene therapies and vaccines.
April 2020:, Thermo Fisher Scientific, announced the availability of Thermo Scientific AcroMetrix Coronavirus 2019 RNA Control, its latest quality control product to monitor and validate COVID-19 molecular diagnostic tests. Thermo Fisher, in an effort to combat the Coronavirus outbreak, designed and developed a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests.
March 2020: Thermo Fisher Scientific, had signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) for cancer.
March 2020: Thermo Fisher Scientific announced acquisition of QIAGEN N.V., leading global provider of molecular diagnostics and sample preparation technologies for approximately $11.5 billion.
February 2020: Thermo Fisher Scientific announced collaboration with NanoPin Technologies, a leading developer of the novel NanoPin diagnostic platform for rapid and quantified results from patient blood samples to advance blood-based infectious disease detection technology through the development of highly sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows.
About Thermo Fisher Scientific
Thermo Fisher Scientific is a world leader in serving science, headquartered in Massachusetts, United States. The company has more than 75,000 colleagues across the globe to help the company to accelerate its life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. The company provides innovative technologies, purchasing convenience and pharmaceutical services through its premier brands like- Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.